<DOC>
	<DOCNO>NCT01073293</DOCNO>
	<brief_summary>This study evaluate whether co-administration first dose V503 REPEVAX™ well tolerate cause non-inferior immune response compare administration REPEVAX™ one month follow first dose V503 .</brief_summary>
	<brief_title>A Study V503 Vaccine Given Concomitantly With REPEVAX™ 11 15 Year Olds ( V503-007 )</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Participant good health Participant 's parent/legal guardian read , understand , complete vaccination report card Participant sexually active plan become sexually active study Participant receive document full primary immunization series diphtheria , tetanus , pertussis , poliovirus ( inactivated and/or oral poliovirus ) , last 5 year . There must 5year interval prior vaccination contain one vaccine antigens . Participant known allergy vaccine component V503 REPEVAX™ Participant severe reaction affect brain ( e.g. , evolve encephalopathy ) within 7 day previous dose pertussiscontaining vaccine Participant progressive severe illness affect brain previous dose tetanus , diphtheria , poliovirus component pertussis combination ( acellular whole cell ) vaccine Participant ever GuillainBarré syndrome brachial neuritis follow previous dose tetanuscontaining vaccine Participant condition contraindication vaccination indicate date package insert REPEVAX™ Participant history severe allergic reaction require medical intervention Participant hemophilia , thrombocytopenia , receive anticoagulation therapy and/or coagulation disorder would contraindicate intramuscular injection Participant concurrently enrol clinical study investigational agent Female participant pregnant Participant donate blood within 1 week prior first study vaccination , intend donate study Participant immunocompromised , immunodeficient , autoimmune condition Participant splenectomy Participant receive immunosuppressive therapy prior year Participant receive immune globulin product bloodderived product last 3 month Participant receive inactivated vaccine ( ) within 14 day live vaccine ( ) within 21 day first study vaccination Participant receive marketed HPV vaccine participate HPV vaccine trial Participant receive tetanus , diphtheria , pertussis , poliovirus ( inactivated and/or oral poliovirus ) vaccination within last 5 year Participant fever ≥100°F within 24 hour vaccination Participant history current condition , therapy , lab abnormality , circumstance best interest participant participate Participant parent/legal guardian unable give assent/consent Participant unlikely adhere study procedure plan relocate study Participant recent history illicit drug alcohol abuse Participant history HPV</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>